Literature DB >> 35225760

First identification of bla NDM-5 producing Escherichia coli from neonates and a HIV infected adult in Tanzania.

Joel Manyahi1,2,3, Sabrina J Moyo1,2,4, Upendo Kibwana2, Richard N Goodman4, Ellie Allman4, Alasdair T M Hubbard4,5, Bjørn Blomberg1,3, Nina Langeland1,3, Adam P Roberts4.   

Abstract

Introduction. Carbapenem-resistant members of the family Enterobacteriaceae are emerging as a global public-health threat and cause substantial challenges in clinical practice.Gap Statement. There is a need for increased and continued genomic surveillance of antimicrobial resistance genes globally in order to detect outbreaks and dissemination of clinically important resistance genes and their associated mobile genetic elements in human pathogens.Aim. To describe the resistance mechanisms of carbapenem-resistant Escherichia coli.Methods. Rectal swabs from neonates and newly diagnosed human immunodeficiency virus (HIV) infected adults were collected between April 2017 and May 2018 and screened for faecal carriage of carbapenamases and OXA-48 producing members of the family Enterobacteriaceae. Bacterial isolates were identified using matrix assisted laser desorption ionization time of flight mass spectrometry. Antimicrobial susceptibility testing was performed by E-test. Whole genomes of carbapenem-resistant E. coli were investigated using a hybrid assembly of Illumina and Oxford Nanopore Technologies sequencing reads.Results. Three carbapenem-resistant E. coli were detected, two from neonates and one from an HIV infected adult. All three isolates carried bla NDM-5. Two E. coli from neonates belonged to ST167 and bla NDM-5 co-existed with bla CTX-M-15 and bla OXA-01, and all were carried on IncFIA type plasmids. The E. coli from the HIV infected adult belonged to ST2083, and carried bla NDM-5 on an IncX3 type plasmid and bla CMY-42 on an IncI type plasmid. All bla NDM-5 carrying plasmids contained conjugation related genes. In addition, E. coli from the HIV infected adult carried three more plasmid types; IncFIA, IncFIB and Col(BS512). One E. coli from a neonate also carried one extra plasmid Col(BS512). All three E. coli harboured resistance genes to fluoroquinolone, aminoglycosides, sulfamethoxazole, trimethoprim, macrolides and tetracycline, carried on the IncFIA type plasmid. Furthermore, E. coli from the neonates carried a chloramphenicol resistance gene (catB3), also on the IncFIA plasmid. All three isolates were susceptible to colistin.Conclusion. This is the first report, to our knowledge, from Tanzania detecting bla NDM-5 producing E. coli. The carbapenemase gene was carried on an IncFIA and IncX3 type plasmids. Our findings highlight the urgent need for a robust antimicrobial resistance (AMR) surveillance system to monitor and rapidly report on the incidence and spread of emerging resistant bacteria in Tanzania.

Entities:  

Keywords:  E. coli; HIV; Tanzania; blaNDM-5; neonates

Mesh:

Substances:

Year:  2022        PMID: 35225760      PMCID: PMC8941953          DOI: 10.1099/jmm.0.001513

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


Background

Infections caused by carbapenem-resistant members of the family Enterobacteriaceae are emerging as a global public health concern. These infections cause substantial challenges in clinical practice as they are associated with increased morbidity and mortality as well as health care costs [1]. Carbapenems are considered a last resort for treatment of infections with multidrug-resistant members of the family Enterobacteriaceae. The remaining alternative treatment options for infections by carbapenem-resistant members of the family Enterobacteriaceae are colistin and tigecycline [2-5], which are expensive, poorly tolerated and often unavailable in low-and middle-income countries. Resistance to carbapenems in Enterobacteriaceae is mainly mediated by the production of carbapenemase enzymes, which hydrolyze carbapenems and all other β-lactam antibiotics. Currently, three classes of carbapenemase enzymes of clinical importance have been identified in pathogenic bacteria. These are Ambler class A (KPC, IMI), class B (NDM, IMP, VIM) and class D (OXA-48) [2, 6]. Previously, carbapenem resistance in Gram-negative bacteria was mainly mediated by production of KPC, IMP, VIM and OXA-48 carbapenemases [6, 7]. In recent years, New Delhi metallo-β-lactamase has received global attention due to its world-wide dissemination, rapid evolution, and high levels of resistance to β-lactam antibiotics [5]. Since the first report of bla NDM-1 in 2008 [8], 24 variants of NDM have been discovered in Gram-negative bacteria [5]. Of the NDM variants, bla NDM-5, which was first detected in in the United Kingdom in 2011 [9], is notable for its elevated resistance to carbapenems compared with other variants [10]. NDM-5 differs from NDM-1 by substitution of two amino acids (Val88Leu and Met154Leu) [11]. The bla NDM-5 is mostly carried on plasmids, which also may carry resistance genes to other antibiotics [12, 13] and catalyse their transfer between bacteria. Several plasmids have been reported to carry bla NDM-5 [5], with IncX3 type plasmid being the most commonly reported [4, 14, 15]. Since its discovery, bla NDM-5 producing has been reported in Asia, mainly PR China [16, 17], Europe [18, 19] and Africa [20, 21]. Meanwhile, in Tanzania, unpublished data shows increased use of carbapenems, but it is unknown whether this has led to an increased incidence of carbapenem resistance. Three Tanzanian studies have described resistance to carbapenems in clinical isolates, documenting the presence of VIM, IMP, NDM-1 and KPC type carbapenemases [22-24], but only one of these studies found NDM-1 carbapenemases in members of the family Enterobacteriaceae [24]. We performed this study to assess the faecal carriage of carbapenem-resistant members of the family Enterobacteriaceae among newly diagnosed HIV infected adults and children hospitalized with fever in Dar es Salaam, Tanzania. We also identified resistance mechanisms to carbapenems and their genetic context using a whole genome sequencing approach.

Methods

Study sites and study participants

Newly diagnosed HIV infected adults were recruited consecutively from six HIV care and treatment centres in Dar es Salaam, Tanzania, namely Amana hospital, Mwananyamala hospital, Temeke hospital, PASADA, Mbagala hospital and Mnazi Mmoja hospital, as part of the double blinded randomized clinical trial, CoTrimResist (ClinicalTrials.gov identifier: NCT03087890) between April 2017 to May 2018. At the same time, children admitted with fever were enrolled in a febrile illness study at four hospitals in Dar es Salaam (Amana, Temeke and Mwananyamala Regional hospitals and Muhimbili National Hospital).

Screening for carbapenemase producing

Rectal swabs were collected from each participant and transported in liquid Cary–Blair medium (Faecal transwab, MWE). Screening for faecal carriage of carbapenamases and OXA-48 producing members of the family Enterobacteriaceae was carried out on CHROMID CARBA SMART (BioMérieux) using two drops (0.1 ml) from an overnight culture in brain–heart infusion broth.

Bacterial identification and antimicrobial susceptibility testing

Carbapenem resistant bacterial isolates which grew on the selective media were identified by matrix assisted laser desorption ionization time of flight mass spectrometry using the Microflex LT instrument and matrix assisted laser desorption ionization Biotyper 3.1 software (Bruker Daltonics). Antibiotic susceptibility testing was determined by E-test (when available), following guidelines from the Clinical and Laboratory Standards Institute [25]. The antimicrobial agents tested were cefotaxime, imipenem, tetracycline, ciprofloxacin, gentamicin and colistin. When E-tests were not available disc diffusion was used to determine meropenem susceptibility according to Clinical and Laboratory Standards Institute guidelines.

Whole genome sequencing

Genomic DNA isolation for short read sequencing was carried out at MicrobesNG (Birmingham, UK). Short read whole genome sequencing was performed using HiSeq X10 (Illumina) by MicrobesNG, which also performed quality filtering and sequencing read trimming. Genomic DNA for long read sequencing was extracted using a Fire Monkey High Molecular Weight DNA Extraction Kit (RevoluGen). Long read sequencing was carried out using a R9.4.1 flow cell (Oxford Nanopore Technologies) on a MinION sequencer. Base calling of the reads was performed with MinKNOW software (v20.06.4) using the Guppy algorithm (v4.0.9). The long-read sequences were trimmed using Porechop (https://github.com/rrwick/Porechop) and filtered using Filtlong (https://github.com/rrwick/Filtlong) with a minimum length threshold of 1000 bp, keeping 90 % of the best reads up to a total of 500 000 000 bp. Long and short read sequences were assembled using Unicycler (v0.4.8.0) [26], running in ‘normal’ mode and the genome was annotated with Prokka (v1.14.6) [27] and the RAST annotation server [28]. Genomes were aligned using both Clinker (v0.0.12) [29] and BRIG (v0.95) [30]. The genomes were visualized using Snapgene (v3.3.4) (https://www.snapgene.com/). All genome assemblies from this study have been deposited in GenBank under the BioProject numbers PRJNA756167 (strain PC-NDM34), PRJNA756168 (strain NDM_12_14482) and PRJNA756169 (strain NDM_11.16372).

Identification of resistance genes and sequence types

For identification of acquired antimicrobial resistance genes, and detection of virulence genes, we used ResFinder v4.1 [31] and virulence Finder 2.0 [32], respectively, from the Centre for Genomic Epidemiology GEE server (http://www.genomicepidemiology.org/). For identification of mobile genetic elements and their relation to antimicrobial resistance genes and virulence factors we used Center of Genomic Epidemiology Mobile Element Finder v1.0.3 [33]. For assignment of multilocus sequence typing (MLST) and clonal complexes we used an online MLST database website (https://pubmlst.org/).

Phylogenetic analysis

Phylogenetic analysis of ST167 whole genomic sequence single nucleotide polymorphisms (SNPs) was performed using CSI phylogeny 1.4 [34]. For comparison, two ST167 from this study were compared with 22 globally available complete whole genome sequences of ST167 (bla NDM-5-positive and bla NDM-5-negative) downloaded from NCBI nucleotide GenBank and the European nucleotide archive (NEA). The phylogenetic tree was visualized using the Fig Tree programme version 1.4.4 (https://github.com/rambaut/figtree/releases).

Comparative analysis of IncFIA and IncX3 carrying bla NDM-5 plasmids

For comparison of the genetic environments surrounding bla NDM-5 on IncFIA and IncX3 plasmids, approximately 20 kb segments were selected including the bla NDM-5 gene from each strain, and annotated using Prokka (v1.14.6) [27] and aligned using Clinker (v0.0.12) [29]. IncFIA and IncX3 plasmids were compared with other available plasmids. A total of 17 IncX3 and 25 IncFI carrying bla NDM-5 plasmids' genome sequences available globally were downloaded from the NCBI ‘nuccore’ database using Entrez Direct as assembled genomes in fasta file format. BRIG v0.95 [30] was used for genomic comparison and to produce the visualisations. For the IncF comparisons, the 1446 NDM-5 plasmid sequence was used as reference and for the IncX3 comparisons the PC34 NDM-5 plasmid sequence was used as a reference. ResFinder v4 [31]. was used to annotate the reference genomes with acquired antimicrobial resistance (AMR) genes.

Results

Bacterial isolates

Three carbapenem resistant designated as PC-NDM34 (from a HIV infected adult), NDM_12_14482, and NDM_11.16372 (both from neonates) were isolated from screening of 737 rectal swabs (537 HIV infected outpatient adults and 200 under five years old inpatient children). Isolate PC-NDM34 was from a 49-year-old individual, an outpatient newly diagnosed with HIV at PASADA HIV care and treatment center in May 2018. The patient had a CD4 count of 132 cell µl−1 with no recent history of hospitalization or antibiotic use. Isolates NDM_12_14482 (22 Jan, 2018) and NDM_11.16372 (05 Feb 2018) were isolated from two neonate patients aged three days from the same ward (Temeke Hospital) two weeks apart in February 2018.

Antimicrobial susceptibility pattern

Table 1 shows the minimum inhibitory concentrations (MICs) of different antimicrobial agents tested against the three isolates. The MICs for all the three isolates to cefotaxime, gentamicin, ciprofloxacin and tetracycline were more than 256 µg ml−1. Meropenem susceptibility was checked for isolates NDM_11.16372 and NDM_12_14482 by disc diffusion, revealing zones of inhibition of 13 mm and 12 mm respectively. For isolate PC-NDM34 meropenem susceptibility was determined by E-test and shown to be 6 µg ml−1. Subsequently, the MICs of these three isolates PC-NDM34, NDM_11.16372 and NDM_12_14482 to imipenem were determined to be 3 µg ml−1, 3 µg ml−1 and 1.5 µg ml−1 respectively. The three isolates were susceptible to colistin at different MIC values as follows; 0.125 µg ml−1 for isolate PC-NDM34, 0.25 µg ml−1 for isolate NDM_11.16372 and 0.19 µg ml−1 for isolate NDM_12_14482.
Table 1.

Susceptibility and MIC of the three carbapenem resistant isolates

Antimicrobial agent

MIC

PC-NDM34

NDM_11.16372

NDM_12_14482

Meropenem

6 µg ml−1

13 mm*

12 mm*

Imipenem

3 µg ml−1

3 µg ml−1

1.5 µg ml−1

Colistin

0.125 µg ml−1

0.25 µg ml−1

0.19 µg ml−1

Cefotaxime

>256 µg ml−1

>256 µg ml−1

>256 µg ml−1

Tetracycline

>256 µg ml−1

>256 µg ml−1

>256 µg ml−1

Ciprofloxacin

>256 µg ml−1

>256 µg ml−1

>256 µg ml−1

Gentamicin

>256 µg ml−1

>256 µg ml−1

>256 µg ml−1

*Meropenem E-tests were unavailable, therefore meropenem disc diffusion assays were used for isolates NDM_11.16372 and NDM_12_14482.

†, AST by E-tests.

Susceptibility and MIC of the three carbapenem resistant isolates Antimicrobial agent MIC PC-NDM34 NDM_11.16372 NDM_12_14482 Meropenem 6 µg ml−1 † 13 mm* 12 mm* Imipenem 3 µg ml−1 † 3 µg ml−1† 1.5 µg ml−1† Colistin 0.125 µg ml−1 † 0.25 µg ml−1 † 0.19 µg ml−1 † Cefotaxime >256 µg ml−1 † >256 µg ml−1 † >256 µg ml−1 † Tetracycline >256 µg ml−1 † >256 µg ml−1 † >256 µg ml−1 † Ciprofloxacin >256 µg ml−1 † >256 µg ml−1 † >256 µg ml−1 † Gentamicin >256 µg ml−1 † >256 µg ml−1 † >256 µg ml−1 † *Meropenem E-tests were unavailable, therefore meropenem disc diffusion assays were used for isolates NDM_11.16372 and NDM_12_14482. †, AST by E-tests.

Resistance determinant genes and association with plasmids

Isolate PC-NDM34 contained six plasmids, IncFIA (109 kb), IncFIB (108 kb), IncI (49 kb), IncX3 (46 kb), Col (BS512) (2 kb), and another unknown plasmid with an approximate size of 5 kb. Isolate NDM_11.16372 contained three plasmids, IncFIA (137 kb), Col (BS512) (2 kb), and another of about 4 kb, and isolate NDM_12_14482 contained one IncFIA plasmid of approximately 137 kb. All three carbapenem resistant carried plasmid-located bla NDM-5. For isolate PC-NDM34, bla NDM-5 was located on an IncX3 type plasmid, while for both isolates NDM_11.16372 and NDM_12_14482 it was located on the IncFIA plasmid. All the bla NDM-5 carrying plasmids also carried genes whose products are predicted to be involved in conjugation. Other β-lactam resistance genes carried by PC-NDM34 were bla TEM-1b and bla CMY-42, located on IncI and IncFIA type plasmids, respectively. The IncFIA type plasmid from P34 harboured other resistance genes including fluoroquinolone-aminoglycosides (aac(6')-Ib-cr); sulfamethoxazole (sul2); trimethoprim (dfr17); aminoglycoside [aac(3)-IId, aph(3')-lb, aadA5]; tetracycline (tetB); and macrolides mph(A). While bla NDM-5 on IncFIA plasmid from both NDM_11.16372 and NDM_12_14482 co-existed with other β-lactam resistance genes (bla TEM-1b, bla OXA-01 and bla CTX-M-15), other resistance genes present on the IncFIA plasmid from both NDM_11.16372 and NDM_12_14482 conferred resistance to fluoroquinolone-aminoglycosides [aac(6')-Ib-cr]; aminoglycosides (aadA2, rmtB); sulfamethoxazole (sul1); trimethoprim (dfr12); chloramphenicol (catB3); tetracycline (tetA); and macrolides mph(A). Table 2 shows resistance genes present in the three isolates.
Table 2.

Genotypic characteristics of the three bla NDM-5 containing

Genotypic characteristics

PC-NDM34

NDM_11.16372

NDM_12_14482

Resistance genes

Beta-lactams

bla TEM-1B

bla TEM-1B

bla TEM-1B

bla NDM-5

bla NDM-5

bla NDM-5

bla CMY-42

bla CTX-M-15

bla CTX-M-15

bla OXA-1

bla OXA-1

Fluoroquinolone-aminoglycosides

aac(6')-Ib-cr

aac(6')-Ib-cr

aac(6')-Ib-cr

Sulfamethoxazole

sul2

sul1

sul1

Trimethoprim

dfr17

dfr12

dfr12

Aminoglycosides

aac(3)-IId, aph(3′)-lb, aadA5

aadA2, rmtB

aadA2, rmtB

Chloramphenicol

catB3

catB3

Tetracycline gene

tetB

tetA

tetA

Mdf

MdfA

MdfA

MdfA

Macrolide

mph(A)

mph(A)

mph(A)

Sequence type (ST)

2083

167

167

Plasmid replicon types

IncFIA

IncFIA,

IncFIA

Col (BS512)

Col (BS512)

IncI

IncIB

IncX3

Unknown

Unknown

Virulence gene

Fimbrial protein

yfcV

EAST-1 heat-stable toxin

astA

Long polar fimbriae

lpfA

Glutamate decarboxylase

gad

gad

gad

Increased serum survival

iss

iss

OMP complement resistance

trat

trat

trat

Heat resistant agglutinin

hra

hra

Hexosyltransferase homology

capU

capU

Tellurium ion resistance protein

terC

terC

terC

Genotypic characteristics of the three bla NDM-5 containing Genotypic characteristics PC-NDM34 NDM_11.16372 NDM_12_14482 Resistance genes Beta-lactams bla TEM-1B bla TEM-1B bla TEM-1B bla NDM-5 bla NDM-5 bla NDM-5 bla CMY-42 bla CTX-M-15 bla CTX-M-15 bla OXA-1 bla OXA-1 Fluoroquinolone-aminoglycosides aac(6')-Ib-cr aac(6')-Ib-cr aac(6')-Ib-cr Sulfamethoxazole sul2 sul1 sul1 Trimethoprim dfr17 dfr12 dfr12 Aminoglycosides aac(3)-IId, aph(3′)-lb, aadA5 aadA2, rmtB aadA2, rmtB Chloramphenicol catB3 catB3 Tetracycline gene tetB tetA tetA Mdf MdfA MdfA MdfA Macrolide mph(A) mph(A) mph(A) Sequence type (ST) 2083 167 167 Plasmid replicon types IncFIA IncFIA, IncFIA Col (BS512) Col (BS512) IncI IncIB IncX3 Unknown Unknown Virulence gene Fimbrial protein yfcV EAST-1 heat-stable toxin astA Long polar fimbriae lpfA Glutamate decarboxylase gad gad gad Increased serum survival iss iss OMP complement resistance trat trat trat Heat resistant agglutinin hra hra Hexosyltransferase homology capU capU Tellurium ion resistance protein terC terC terC

Multi-locus sequence typing (MLST)

MLST analysis revealed that both NDM_12_14482 and NDM_11.16372, the isolates from neonates, harbouring bla NDM-5 belonged to ST167 (ST10 clonal complex). In contrast, PC-NDM34 bla NDM-5, isolated from an adult HIV infected patient, belonged to ST2083. A total of 22 ST167 (bla NDM-5-positive and bla NDM-5-negative) globally available from GenBank and the European nucleotide archive (see Supplementary file 1, available with the online version of this article, for accession numbers) were compared with two ST167 strains from this study. The SNP analysis of all ST167 differed by between 2 and 3410 SNPs, revealing the high genetic diversity of this high-risk clone. The phylogenetic analysis revealed that ST167 was clustered into two distinct clades with multiple subclades (Fig. 1). The two ST167 from this study had a SNP difference of two SNPs and were clustered in clades with other ST167 from PR China, Italy and Myanmar and two with undetermined origins. In this clade, the SNP difference between this study’s ST167 and other ST 167 ranged between 880 and 1312 SNPs.
Fig. 1.

Phylogenetic tree ST167 (bla NDM-5-positive and bla NDM-5-negative). Countries of origin of each ST167 have been highlighted in the tree, not determined indicates that the origin is not known.

Phylogenetic tree ST167 (bla NDM-5-positive and bla NDM-5-negative). Countries of origin of each ST167 have been highlighted in the tree, not determined indicates that the origin is not known. This analysis reveals that the two isolates (NDM_12_14482 and NDM_11.16372 ) which were isolated from neonates, were closely related and probably arose from the same source. Furthermore, this revealed that the isolates from neonates were more distantly related to the ST167 isolates from other part of the world.

Genetic environment for the bla NDM-5 carrying plasmids

Comparative analysis of plasmids carrying bla NDM-5, revealed the IncFIA type plasmids from NDM_12_14482 and NDM_11.16372 harboured 100 % identical sequences and bla NDM-5 co-existed with several resistance determinant genes (Fig. 2).
Fig. 2.

Comparative analysis of the three plasmids carrying bla NDM-5, image produced using BRIG. A comparison between the three bla NDM-5 positive plasmids across the three strains, each coloured accordingly. The reference genome was the plasmid of the isolate 14 482. The inner black ring represents GC content of the reference sequence. AMR genes are labelled. 14482= NDM_12_14482, 16372= NDM_11.16372 and PC34= PC-NDM34.

Comparative analysis of the three plasmids carrying bla NDM-5, image produced using BRIG. A comparison between the three bla NDM-5 positive plasmids across the three strains, each coloured accordingly. The reference genome was the plasmid of the isolate 14 482. The inner black ring represents GC content of the reference sequence. AMR genes are labelled. 14482= NDM_12_14482, 16372= NDM_11.16372 and PC34= PC-NDM34. Comparative analysis of the genetic environments of bla NDM-5 in IncX3 and IncFIA type plasmids revealed similar genetic context downstream of bla NDM-5 flanked by conserved ble MBL–trpF–DsbD. In the IncX3 plasmid bla NDM-5 was flanked upstream by IS5, and in the IncFIA type plasmid it was flanked upstream by IS26 interrupted by a gene predicted to encode a conserved hypothetical protein (Fig. 3). In the IncX3 type plasmid, bla NDM5–ble MBL–trpF–DsbD was flanked by IS5 upstream and IS26 downstream (Fig. 4). In the IncFIA plasmid, further downstream of bla NDM5–ble MBL–trpF–DsbD were a set of several genes including sul-2, ant(3′)-Ia, dfrA12 and IntI1. The bla NDM-5 –IntI1 genetic complex was flanked on both ends by IS26 (Fig. 3).
Fig. 3.

Comparison of bla NDM-5 genetic context on 16372 (IncFIA), 14482 (IncFIA) and PC34 (IncX3) plasmids. A sequence comparison between the genetic environments surrounding bla NDM-5 in the three strains. Approximately 20 kb segments were selected including the bla NDM-5 gene from each strain, these were annotated using Prokka and aligned using clinker. Unique sequences are coloured according to feature. Those features which are homologous across all three strains are highlighted with asterisks. 14482= NDM_12_14482, 16372= NDM_11.16372 and PC34= PC-NDM34.

Fig. 4.

Genetic context of bla NDM-5 on the IncX3 plasmid (PC-NDM34).

Comparison of bla NDM-5 genetic context on 16372 (IncFIA), 14482 (IncFIA) and PC34 (IncX3) plasmids. A sequence comparison between the genetic environments surrounding bla NDM-5 in the three strains. Approximately 20 kb segments were selected including the bla NDM-5 gene from each strain, these were annotated using Prokka and aligned using clinker. Unique sequences are coloured according to feature. Those features which are homologous across all three strains are highlighted with asterisks. 14482= NDM_12_14482, 16372= NDM_11.16372 and PC34= PC-NDM34. Genetic context of bla NDM-5 on the IncX3 plasmid (PC-NDM34). Fig. 5 shows the results of the comparative analysis of the fully sequenced bla NDM-5 carrying IncFIA plasmids from this study (NDM_12_14482 and NDM_11.16372) and the IncF plasmids (bla NDM-5-positive and bla NDM-5-negative) of global representatives (see Supplementary file 1 for accession numbers). Structural similarities (downstream) were observed within the genetic environment surrounding bla NDM5 (Fig. 5). The NDM_12_14482 and NDM_11.16372 plasmid sequences differ slightly compared with other global IncF plasmids.
Fig. 5.

A comparative analysis of the two IncFIA plasmids (16372 and 14482) containing bla NDM-5 against IncF plasmids identified globally. BRIG was used for genomic comparison and visualization. Plasmid (137 Kb) from isolate NDM_12.14482 containing bla NDM-5 was used as the reference. Sequences are named using their accession numbers. (16372=NDM_11.16372 and 14482=NDM_12.14482).

A comparative analysis of the two IncFIA plasmids (16372 and 14482) containing bla NDM-5 against IncF plasmids identified globally. BRIG was used for genomic comparison and visualization. Plasmid (137 Kb) from isolate NDM_12.14482 containing bla NDM-5 was used as the reference. Sequences are named using their accession numbers. (16372=NDM_11.16372 and 14482=NDM_12.14482). Comparative analysis of bla NDM-5 carrying IncX3 plasmids is depicted in Fig. 6, comparing PC-NDM34 from this study with globally identified IncX3 plasmids (see Supplementary file 1 for accession numbers). The genetic context of bla NDM-5 on IncX3 plasmids was similar downstream. The genetic sequence of PC-NDM34 IncX3 was almost identical to those of most other global IncX3 plasmids, with slight differences observed (Fig. 6).
Fig. 6.

A comparative analysis of the IncX3 (PC34) plasmid of the isolate PC-NDM34 against IncX3 plasmids identified globally. BRIG was used for genomic comparison and visualization. The plasmid (46 Kb) from isolate PC-NDM34 containing bla NDM-5 was used as a reference. All sequences were of plasmids containing IncX3 except for CP034348 which contained an IncX1 plasmid. Sequences are named using their accession numbers.

A comparative analysis of the IncX3 (PC34) plasmid of the isolate PC-NDM34 against IncX3 plasmids identified globally. BRIG was used for genomic comparison and visualization. The plasmid (46 Kb) from isolate PC-NDM34 containing bla NDM-5 was used as a reference. All sequences were of plasmids containing IncX3 except for CP034348 which contained an IncX1 plasmid. Sequences are named using their accession numbers.

Discussion

This is the first report from Tanzania and East Africa, to our knowledge, on the detection of bla NDM-5 producing . We found three carrying bla NDM-5, one from a newly diagnosed HIV infected patient and two from admitted neonates. The comparative genomic analysis of bla NDM-5 producing revealed that the carbapenemase gene was plasmid located and that these plasmids also carried resistance gene determinants to other antibiotics, including aminoglycosides, fluoroquinolones, macrolides, tetracycline, trimethoprim, sulfamethoxazole and chloramphenicol. The finding of carbapenem resistance conferred by the bla NDM-5 gene in Tanzania is of the great concern, since these isolates also were resistant to virtually all other antibiotics commonly used in Tanzania. Carbapenems have been used as the last alternative for treatment of severe infections caused by multi-drug resistant Gram-negative bacteria infection, the emergence of carbapenem resistance severely limits treatment options for these patients. Lately, the use of carbapenems in Tanzania has been frequent [35], and increased use is anticipated in the future due to increased extended spectrum beta-lactamase (ESBL) producing bacterial infections [36]. Increasing carbapenem use will increase selection for horizontal gene transfer events and, therefore, the movement of the gene and human movement will increase dissemination of carbapenem resistant bacteria around the country. To date, reports on bla NDM-5 producing Gram-negative bacteria from Africa have been uncommon. In Africa, bla NDM-5 was first reported in Algeria in three recovered from urine and blood in 2012 [20]. Since then, bla NDM-5 in humans has been reported in Egypt [37], Angola [38], South Africa [39], Nigeria [40], Chad [15] and Malawi [41, 42]. Recently, bla NDM-5 producing have been detected in Mali from one outpatient [21] and in Mozambique in a patient with a bloodstream infection [12]. The reason for increased detection of bla NDM-5-producing Gram-negative bacteria in Africa is not known, it could be independent introduction from the rest of the world. Our three bla NDM-5 were isolated from patients with no history of travel beyond Tanzania. It is therefore likely that the patients have acquired the bla NDM-5 producing in Tanzania or their resident had acquired bla NDM-5 from a transient donor also in Tanzania. In analysing mobile genetic elements and their relationship with resistance genes, we found that the bla NDM-5 producing ST2085 from the HIV infected patient was located on an IncX3 type plasmid. Similarly, a recent published study from Malawi reported detection of blaNDM-5 contained in an IncX3 plasmid from ST2085 isolated from the stool of an HIV-infected adult [42]. The results of previous studies have demonstrated that bla NDM-5 is commonly carried on IncX3 type plasmid [13, 15, 43–45]. In addition, the results of previous studies have indicated that the IncX3 type plasmid plays an important role in dissemination of bla NDM-5 in members of the family [13, 14, 21]. This hypothesis has been supported by the results of several experimental conjugation studies, where bla NDM-5 carrying IncX3 type plasmids were able to be successfully transferred amongst, and between, different species of the family [14, 43]. The bla NDM-5 carrying IncX3 plasmid from this study revealed almost identical plasmid sequence to globally identified IncX3 plasmid. Our finding of an IncX3 type plasmid associated with bla NDM-5 in a newly diagnosed HIV patient from the community setting in Tanzania is concerning, since this plasmid is epidemic and has been shown to carry multiple carbapenemase genes, including bla NDM-5, and has a high potential to efficiently disseminate globally. Spread of bla NDM-5 in the community has serious implication since bla NDM-5 carrying isolates also display multidrug resistance [13]. IncF type plasmids have also been shown to contribute to the dissemination of bla NDM-5 among [17, 18, 46]. In this study, we observed that the bla NDM-5 in from neonates was carried on IncFIA type plasmids. The bla NDM-5 from these isolates co-existed with bla CTX-M-15, bla TEM-1B and bla OXA-1 located on the IncFIA plasmid. Other recent studies in Africa and elsewhere have observed co-harbouring of bla NDM-5 and bla CTX-15, bla TEM-1B, bla OXA-1 in the same plasmid type in [3, 12, 46]. Co-localization of bla NDM-5 and extended spectrum β-lactamase (bla CTX-M-15) plus other resistance genes in the same plasmid could increase the dissemination of multiple resistances in a single gene transfer event. Furthermore, the two bla NDM-5 producing from neonates had similar resistance gene determinants, virulence genes and ST167, indicating that the isolates were likely to be clonal. Chromosomal DNA SNP analysis of the two isolates also revealed a pairwise distance of two SNPs. This finding indicates that these two isolates were closely related and the source of spread was likely to be the same. It implies there was probably local transmission of bla NDM-5 producing E. coli. E. coli ST167 carrying bla NDM-5 has been reported in South Africa in one inpatient with nosocomial infection [39]. Recently, ST167 has been regarded as a high-risk and successful epidemic clone involved in transmission of the bla NDM-5 gene [19, 43]. Furthermore, bla NDM-5 producing ST167 has the potential for global dissemination due its combination of resistance and virulence genes [43]. The bla NDM-5 producing ST167 has been reported in neonatal and adult infections in PR China [3, 16, 17, 47], the USA [48], Europe [18] and Africa [39]. Similar to our finding, an ST167 strain co-producing bla NDM-5, bla CTX-M-15 and bla OXA-1 has been reported in bacteria causing infection in PR China [3]. Phylogenetic analysis revealed the ST167 strains are clonally diverse and our study isolates were phylogenetically distant from global circulating ST167, (Fig. 1). Our study revealed in all three , that the bla NDM-5 on each plasmid was flanked by highly a conserved region (ble MBL–trpF–DsbD) downstream, indicating that the region is very probably transferring between replicons (plasmids) and between bacteria as a single unit. The upstream genetic environment of bla NDM5 in two plasmids were different. Previous in-depth analysis of the genetic environment of bla NDM-5 genes revealed that the bla NDM-5 is flanked upstream by ISAba125 and downstream by ble MBL–trpF–DsbD (IS3000–IS5–ΔISAba125–bla NDM-5–ble MBL –trpT–DsbD) [21, 49, 50]. In this study we found complete deletion of IS3000–IS5–ΔISAba125 upstream of bla NDM-5 in the IncFIA plasmid from the neonates. In the IncX3 plasmid, complete deletion of ΔISAba125 was observed and the IS3000–IS5 element was interrupted by IS30.

Conclusion

This is the first detection of bla NDM-5 producing in Tanzania, to our knowledge. We found bla NDM-5 in ST167 located on an IncFIA plasmid colonizing the gut of two neonates and bla NDM-5 producing ST2083 located on an IncX3 plasmid colonizing the gut of an outpatient newly diagnosed with HIV. Our findings highlight the urgent need for a robust AMR surveillance system to monitor and rapidly report on the incidence and spread of emerging resistant bacteria in Tanzania. In addition, long-term infection prevention and control procedures and antimicrobial stewardship policies need to be introduced, optimized and maintained to curb the spread of resistant bacteria within healthcare environments. Click here for additional data file.
  49 in total

1.  High Rate of Association of 16S rRNA Methylases and Carbapenemases in Enterobacteriaceae Recovered from Hospitalized Children in Angola.

Authors:  Laurent Poirel; Juliette Goutines; Marta Aires-de-Sousa; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Spread of NDM-5 and OXA-181 Carbapenemase-Producing Escherichia coli in Chad.

Authors:  Yann Dumont; Fabrice Compain; Sylvain Godreuil; Oumar Ouchar Mahamat; Manon Lounnas; Mallorie Hide; Abelsalam Tidjani; Julio Benavides; Abibatou Diack; Calèbe Somasse; Kadidja Gamougam; Christian Carrière; Dominique Decré; Anne-Laure Bañuls; Hélène Jean-Pierre
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  First description of IncX3 NDM-5-producing plasmid within Escherichia coli ST448 in Mali.

Authors:  Anaëlle Muggeo; Aminata Maiga; Ibrahim Maiga; Lucien Brasme; Oumar Agaly Dicko; Christophe de Champs; Thomas Guillard
Journal:  J Med Microbiol       Date:  2020-04-24       Impact factor: 2.472

4.  First Identification and genomic characterization of multidrug-resistant carbapenemase-producing Enterobacteriaceae clinical isolates in Malawi, Africa.

Authors:  Geoffrey P Kumwenda; Yo Sugawara; Ryuichiro Abe; Yukihiro Akeda; Watipaso Kasambara; Kenneth Chizani; Dan Takeuchi; Noriko Sakamoto; Kazunori Tomono; Shigeyuki Hamada
Journal:  J Med Microbiol       Date:  2019-10-29       Impact factor: 2.472

Review 5.  Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  Biomed Res Int       Date:  2014-03-26       Impact factor: 3.411

6.  Characterization Of bla NDM-5-Positive Escherichia coli Prevalent In A University Hospital In Eastern China.

Authors:  Pengfei Sun; Wenying Xia; Genyan Liu; Xu Huang; Chenjie Tang; Chengcheng Liu; Yuqiao Xu; Fang Ni; Yaning Mei; Shiyang Pan
Journal:  Infect Drug Resist       Date:  2019-09-24       Impact factor: 4.003

7.  Dissemination of blaNDM-5 gene via an IncX3-type plasmid among non-clonal Escherichia coli in China.

Authors:  Xi Li; Ying Fu; Mengyuan Shen; Danyan Huang; Xiaoxing Du; Qingfeng Hu; Yonglie Zhou; Dairong Wang; Yunsong Yu
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-26       Impact factor: 4.887

8.  Multiple NDM-5-Expressing Escherichia Coli Isolates From an Immunocompromised Pediatric Host.

Authors:  Tim Flerlage; Jessica N Brazelton de Cardenas; Cherilyn D Garner; Nur A Hasan; Hiren Karathia; Amr Qudeimat; Gabriela Maron; Randall Hayden
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

9.  Molecular Mechanisms and Epidemiology of Carbapenem-Resistant Escherichia coli Isolated from Chinese Patients During 2002-2017.

Authors:  Xuebin Tian; Xiangkuo Zheng; Yao Sun; Renchi Fang; Siqin Zhang; Xiucai Zhang; Jie Lin; Jianming Cao; Tieli Zhou
Journal:  Infect Drug Resist       Date:  2020-02-17       Impact factor: 4.003

10.  Point prevalence survey of antimicrobial use in three hospitals in North-Eastern Tanzania.

Authors:  Pius G Horumpende; Stephen E Mshana; Elise F Mouw; Blandina T Mmbaga; Jaffu O Chilongola; Quirijn de Mast
Journal:  Antimicrob Resist Infect Control       Date:  2020-09-07       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.